This debate produced two well-constructed but fundamentally opposed narratives, and after weighing them carefully, I land closer to balanced than to either extreme — hence Hold rather than committing to Buy/Overweight or Underweight/Sell. The bull's strongest pillars are real and cannot be dismissed: (1) ZENBEXUS received actual FDA approval as a first-in-class CELMoD with MRD-negative CR data — this is a genuine clinical milestone, not narrative spin; (2) Deleveraging is quantifiable and accelerating ($50.9B → $45.1B in 12 months, current ratio 1.21 → 1.53, FCF/dividend coverage 2.5x); and (3) Q2 2026 was genuinely strong ($3.32B net income, +153% YoY). These argue against a Sell. But the bear landed the more damaging counterpoints: (1) The bull frames "patent cliff" around Revlimid, but the actual underappreciated risk is Eliquis at ~$13B annually facing 2026-2027 generic erosion — that's a far larger franchise loss than Revlimid was, and it is NOT priced in; (2) The 59% rally has largely consumed the ZENBEXUS approval catalyst — buying it now is buying the announcement, not the launch; (3) The technical picture genuinely looks tired: three failed attempts at $68.42-68.64, MACD histogram at +0.01 (momentum exhaustion, not "maturation"), and RSI cooling from 72 → 60 (distribution, not consolidation); and (4) The macro backdrop (88% probability of zero Fed cuts per Polymarket) caps multiple expansion and makes a 3.73% yield materially less attractive vs. 5%+ money market funds. The bull's framing of sequential +12.9% Q/Q revenue growth is misleading — bear correctly notes YoY is only 5.7% and seasonal pharma purchasing patterns drive sequential Q1→Q2. The bull's dismissal of negative tangible book and the Cytokinetics suit (disclosed the same week as ZENBEXUS approval) is incomplete risk analysis. Where I disagree with both sides: this is NOT a binary "buy the transformation vs. sell the cliff" situation. The fundamentals support a constructive long-term view (deleveraging, pipeline diversification, cash generation), while near-term setup argues for patience. The path of least regret is to maintain exposure but not add at $67 with Eliquis erosion unquantified and a macro that caps multiple expansion.

POSITION STRATEGY: Maintain current BMY position; do not add at $66-67 levels. Do not initiate new positions until either (a) a pullback to $61-62 (50 SMA) confirms support and improves risk/reward, (b) ZENBEXUS Q3 2026 launch data validates blockbuster-class uptake, or (c) Eliquis erosion trajectory is quantified and digestible.

UPGRADE TRIGGERS: Pullback to 50 SMA ($61.32) on healthy volume with technical reset (MACD reloading, RSI reset below 50) — buy zone with better risk/reward; Q3 2026 print (late October) shows ZENBEXUS revenue tracking toward $1B+ annualized and Cobenfy ramp above $300M/quarter; Confirmation that Eliquis erosion in early 2027 is more gradual than feared; Multiple compression below 9.5x forward earnings.

DOWNGRADE TRIGGERS: Break of 50 SMA ($61.32) on volume — mechanical exit signal for income holders; Failed breakout below $68 followed by break of 10 EMA ($66.53) — early warning of trend deterioration; ZENBEXUS Q3 launch tracking materially below expectations (sub-$200M/quarter annualized); Adverse Eliquis patent ruling that accelerates generic entry timeline; Dividend cut signal (any commentary suggesting payout review).

INCOME/YIELD HOLDERS: The 3.73% yield is genuinely attractive only if Eliquis erosion is gradual and dividend coverage stays above 2x FCF. If Eliquis erosion compresses FCF meaningfully, the yield becomes a yield trap — set a hard stop at 50 SMA ($61.32). Do NOT chase yield at these levels when 5%+ money market alternatives are available in a higher-for-longer rate environment.

WATCH LIST: Priority order: (1) October 2026 — Q3 earnings with first ZENBEXUS revenue print; (2) Within weeks — Camzyos adolescent label decision (confirmed dated catalyst); (3) Late 2026 / Early 2027 — Eliquis erosion data points from competitor launches; (4) Ongoing — Cytokinetics litigation developments (filed mid-2026); (5) Macro — Fed pivot signals (Polymarket currently 88% no cuts, would meaningfully shift if this inverts).

The investment plan presents a balanced case that argues against both adding exposure at current levels ($66-67) and exiting. The ZENBEXUS FDA approval and accelerating deleveraging ($50.9B → $45.1B) are genuine positives, but the 59% rally has largely consumed the approval catalyst while leaving the far larger Eliquis risk (~$13B franchise facing 2026-2027 generic erosion) unpriced. Technicals confirm fatigue — three failed attempts at $68.42-68.64, MACD histogram at +0.01, and RSI cooling from 72 → 60 — consistent with distribution rather than consolidation. With 88% Polymarket probability of zero Fed cuts capping multiple expansion and 5%+ money market alternatives available, the 3.73% yield is materially less attractive, making this a "right company, wrong timing" setup where patience is the alpha.

Stop loss: $61.32

Sizing: Maintain current allocation; do not add above $65. Add only on confirmed pullback to 50 SMA ($61.32) with technical reset.